Vyrologix Long Hauler Study Dr. Norman Gaylis,
Post# of 148176
(Total Views: 466)
Posted On: 01/20/2021 1:16:05 PM
Vyrologix Long Hauler Study
Dr. Norman Gaylis, a rheumatologist in FL, is looking for long haulers for a study using Vyrologix. The top article is from a news station in Miami. It does not name the drug. The second article below is a tweet looking for participants for that trial and it does mention Vyrologix. Trial starts in February.
A rheumatologist in Aventura needs volunteers for a double-blind, placebo-controlled pilot study on a drug that might be a candidate to treat COVID-19 long-hauler syndrome, if it gets approved down the line.
The long-hauler syndrome is "thought to be a result of a post-reactive inflammatory response to the COVID that affects the immune system—which creates many different symptoms in the patient," said Dr. Norman Gaylis, who's conducting the study.
Gaylis said he constantly sees patients with these symptoms—which may persist for months—even after testing negative for the virus. They experience fatigue, headaches, joint pain, brain fog, shortness of breath or skin rashes that won’t go away.
"People shouldn’t feel like they need to just live with it," Gaylis said. "That’s been unfortunately a frustration—that nobody really knows or does anything to help many of these patients. So getting them to come and be evaluated, and then if they’re candidates for the study, great."
When someone develops COVID-19, the body launches an immune response and tries to protect itself. But there's an exaggerated inflammatory reaction that can make a person much sicker. The drug Gaylis is studying, Vyrologix, is a monoclonal antibody researchers hope will be able to block that reaction. Monoclonal antibodies are man-made proteins that function like human antibodies in our immune system.
The unpaid study is slated to begin in February, pending an official approval by the Food and Drug Administration and an institutional review board. Participants must have proof of a positive test in the past and experience long-hauler syndrome.
For more information, call Dr. Gaylis's office at 305-652-6676 or email ngaylis@rheum-care.com.
https://www.wlrn.org/local-news/2021-01-18/so...ibody-drug
Peaceful Warrior
@DrizztMom
Jan 19
Attention #LongHaulers in Florida
#Vyrologix / #Leronlimab by Cytodyn 1/2 ‘The long-hauler syndrome is "thought to be a result of a post-reactive inflammatory response to the #COVID that affects the immune system—...
ngaylis@rheum-care.com.
...2/2 which creates many different symptoms in the patient," said Dr. Norman Gaylis, who's conducting the study. The drug #Vyrologix, (#Leronlimab) is a monoclonal antibody researchers hope will be able to block that reaction.”
7:13 AM · Jan 19, 2021·Twitter for iPhone
https://twitter.com/DrizztMom/status/1351518111393075202
Dr. Norman Gaylis, a rheumatologist in FL, is looking for long haulers for a study using Vyrologix. The top article is from a news station in Miami. It does not name the drug. The second article below is a tweet looking for participants for that trial and it does mention Vyrologix. Trial starts in February.
A rheumatologist in Aventura needs volunteers for a double-blind, placebo-controlled pilot study on a drug that might be a candidate to treat COVID-19 long-hauler syndrome, if it gets approved down the line.
The long-hauler syndrome is "thought to be a result of a post-reactive inflammatory response to the COVID that affects the immune system—which creates many different symptoms in the patient," said Dr. Norman Gaylis, who's conducting the study.
Gaylis said he constantly sees patients with these symptoms—which may persist for months—even after testing negative for the virus. They experience fatigue, headaches, joint pain, brain fog, shortness of breath or skin rashes that won’t go away.
"People shouldn’t feel like they need to just live with it," Gaylis said. "That’s been unfortunately a frustration—that nobody really knows or does anything to help many of these patients. So getting them to come and be evaluated, and then if they’re candidates for the study, great."
When someone develops COVID-19, the body launches an immune response and tries to protect itself. But there's an exaggerated inflammatory reaction that can make a person much sicker. The drug Gaylis is studying, Vyrologix, is a monoclonal antibody researchers hope will be able to block that reaction. Monoclonal antibodies are man-made proteins that function like human antibodies in our immune system.
The unpaid study is slated to begin in February, pending an official approval by the Food and Drug Administration and an institutional review board. Participants must have proof of a positive test in the past and experience long-hauler syndrome.
For more information, call Dr. Gaylis's office at 305-652-6676 or email ngaylis@rheum-care.com.
https://www.wlrn.org/local-news/2021-01-18/so...ibody-drug
Peaceful Warrior
@DrizztMom
Jan 19
Attention #LongHaulers in Florida
#Vyrologix / #Leronlimab by Cytodyn 1/2 ‘The long-hauler syndrome is "thought to be a result of a post-reactive inflammatory response to the #COVID that affects the immune system—...
ngaylis@rheum-care.com.
...2/2 which creates many different symptoms in the patient," said Dr. Norman Gaylis, who's conducting the study. The drug #Vyrologix, (#Leronlimab) is a monoclonal antibody researchers hope will be able to block that reaction.”
7:13 AM · Jan 19, 2021·Twitter for iPhone
https://twitter.com/DrizztMom/status/1351518111393075202
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼